StoneX Group’s ProShares Ultra CRCL CRCA Stock Holding History

StoneX Group’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$288K	Buy	+6,511	New	+$251K	0.01%	850
2026 Q1	–	Sell	-6,027	Closed	-$243K	–	1303
2025 Q4	$243K	Buy	+6,027	New	+$517K	0.01%	791

Other funds holding CRCA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

StoneX Group's CRCA Position: Q2 2026 in Review

StoneX Group opened a new position in ProShares Ultra CRCL (CRCA) in Q2 2026: 6,511 shares worth $288K. The stake represents 0.01% of the portfolio and ranks #850 among its holdings. This is a return to the name: StoneX Group previously reported a position in CRCA as recently as Q4 2025.

StoneX Group first reported a position in CRCA in Q4 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

StoneX Group held 6,511 shares of ProShares Ultra CRCL worth $288K as of Q2 2026.
ProShares Ultra CRCL was a new StoneX Group position in Q2 2026.
ProShares Ultra CRCL made up 0.01% of StoneX Group's portfolio in Q2 2026, its #850 holding.
StoneX Group first reported a position in ProShares Ultra CRCL in Q4 2025 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.